From Injections to Pills: Breaking Down the New Oral GLP-1 Data
Dr. Spencer and Dr. Karl sit down with Dr. Sean Wharton, lead author on the OASIS-4 and ATTAIN-1 trials, to unpack the groundbreaking data behind the new oral GLP-1 medications. They discuss how oral semaglutide and orforglipron compare to injectables, what makes these molecules unique, and why 2026 could be the year obesity care changes forever.
Audio is streamed directly from the publisher (injector.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Show Notes:
In this episode of Docs Who Lift, the Nadolsky brothers welcome back Dr. Sean Wharton, clinical trialist and one of the leading researchers behind the next generation of oral GLP-1 medications. Together, they break down:
The OASIS-4 trial results on 25mg oral semaglutide and how it stacks up to injectable Wegovy
How orforglipron, Eli Lilly’s new small-molecule GLP-1, differs from peptide-based drugs
Why these new therapies could make weight management more accessible and affordable
The fascinating pharmacology behind “snack molecules” and small-molecule receptor agonists
Common misconceptions about bioavailability, dosing, and side effects
The potential role of oral GLP-1s for patients with mild obesity or cardiometabolic disease
Whether you’re a clinician, researcher, or patient curious about the future of obesity medicine, this conversation offers a clear look at how science is shifting toward needle-free solutions.
Oasis 1 Trial Link
Oasis 4 Trial Link
Attain 1 Trial Link
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.